Mako Medical Laboratories, LLC

Mako Medical Laboratories, LLC was paid $97.92M by Medicaid between Jan 2018 and Dec 2024, across 270 billing codes. Its largest line is G0482, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed — 21% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in North Carolina

Rank by total paid#5 of 128

Median peer was paid$268K

This provider vs. median365×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	233,429	$15.85M
2019	244,102	$13.94M
2020	315,491	$14.11M
2021	472,389	$16.22M
2022	479,215	$13.18M
2023	651,792	$11.65M
2024incomplete	715,272	$12.97M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	21%	203,443	102,137	$20.82M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	16%	114,323	70,168	$15.62M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	13%	314,470	186,094	$13.04M
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	12%	221,043	130,441	$11.38M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	11%	201,494	130,242	$10.53M
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	4.3%	74,723	42,910	$4.20M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.1%	18,168	15,947	$2.03M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.4%	85,945	50,628	$1.40M
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	1.3%	64,645	57,328	$1.27M
80061	Lipid panel	1.0%	108,601	95,174	$982K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	45,094	38,212	$922K
84443	Thyroid stimulating hormone (TSH)	<1%	86,812	76,256	$908K

258 more codes

80053	Comprehensive metabolic panel	<1%	146,688	$870K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	45,113	$849K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	18,973	$757K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	51,419	$687K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	131,204	$680K
83036	Hemoglobin; glycosylated (A1C)	<1%	92,686	$614K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	34,040	$593K
80074		<1%	29,823	$577K
80050	General health panel	<1%	31,686	$490K
87631		<1%	4,156	$373K
82607		<1%	37,444	$360K
87522	Neg quan hep c or qual rna	<1%	15,991	$280K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	2,277	$275K
87481		<1%	11,520	$264K
86803		<1%	23,944	$243K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	2,348	$235K
84439		<1%	34,947	$233K
87086	Culture, bacterial; quantitative colony count, urine	<1%	30,718	$204K
86481		<1%	4,888	$188K
87804	Infectious agent antigen detection by immunoassay; Influenza, each type	<1%	9,682	$180K
82746		<1%	19,533	$177K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	4,311	$176K
87640		<1%	7,930	$171K
36415	Collection of venous blood by venipuncture	<1%	120,717	$168K
87511		<1%	8,101	$162K
86003		<1%	1,803	$161K
84481		<1%	12,347	$160K
82652		<1%	6,323	$159K
87902		<1%	1,133	$146K
85027		<1%	33,426	$138K
86592		<1%	49,452	$137K
87581		<1%	5,973	$133K
87486		<1%	5,965	$132K
87070		<1%	12,541	$120K
84146		<1%	6,896	$119K
80048	Basic metabolic panel (calcium, ionized)	<1%	19,909	$103K
87541		<1%	4,444	$102K
87186		<1%	13,383	$100K
87340		<1%	15,530	$99K
84403		<1%	6,044	$98K
83735		<1%	25,326	$95K
86706		<1%	15,082	$88K
87088		<1%	12,800	$86K
87430		<1%	10,887	$84K
87653		<1%	4,019	$84K
82728		<1%	9,680	$80K
80164		<1%	7,769	$80K
84153		<1%	6,788	$79K
87500		<1%	3,719	$78K
86696		<1%	5,436	$77K
83525		<1%	7,543	$74K
83550		<1%	12,764	$70K
83540		<1%	16,442	$69K
87150		<1%	1,117	$67K
83880		<1%	3,591	$66K
87556		<1%	1,705	$66K
87498		<1%	3,514	$62K
81025		<1%	13,145	$60K
84436		<1%	15,959	$58K
87536		<1%	1,598	$57K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	1,808	$55K
84479		<1%	15,218	$54K
80076		<1%	8,683	$52K
87400		<1%	6,522	$52K
82670		<1%	2,891	$50K
86695		<1%	5,339	$48K
87532		<1%	2,661	$44K
86360		<1%	1,061	$42K
83970		<1%	1,933	$41K
83013		<1%	764	$40K
87807		<1%	3,776	$37K
81001		<1%	28,311	$36K
87507		<1%	88	$35K
82043		<1%	10,154	$34K
83001		<1%	2,736	$34K
86359		<1%	1,057	$34K
86704		<1%	5,210	$31K
84402		<1%	2,397	$31K
87529		<1%	750	$28K
84702		<1%	3,626	$27K
86038		<1%	3,179	$25K
86376		<1%	2,726	$24K
86705		<1%	4,914	$23K
84703		<1%	4,746	$23K
80178		<1%	4,153	$22K
84144		<1%	1,578	$21K
86140		<1%	5,924	$21K
82140		<1%	1,854	$21K
82570		<1%	7,663	$21K
82785		<1%	1,419	$20K
83002		<1%	1,680	$19K
83655		<1%	2,066	$18K
86709		<1%	3,704	$18K
81003		<1%	12,071	$18K
82977		<1%	3,955	$18K
84100		<1%	5,968	$18K
83721		<1%	2,749	$17K
84270		<1%	1,519	$16K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	189	$16K
87081		<1%	2,881	$16K
86665		<1%	866	$15K
87075		<1%	1,874	$15K
83090		<1%	1,089	$14K
84550		<1%	4,666	$14K
83690		<1%	3,186	$14K
86790		<1%	582	$13K
82150		<1%	3,057	$12K
86762		<1%	1,211	$12K
80177		<1%	1,538	$11K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	723	$11K
86235		<1%	203	$10K
85652		<1%	5,750	$10K
86780		<1%	1,177	$10K
86430		<1%	2,516	$9K
84681		<1%	861	$9K
85610		<1%	4,371	$9K
87205		<1%	2,402	$9K
82248		<1%	2,304	$8K
87341		<1%	1,084	$8K
80159		<1%	971	$8K
86480		<1%	301	$8K
83516		<1%	595	$7K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	114	$7K
86800		<1%	881	$6K
86328		<1%	201	$6K
84425		<1%	635	$6K
82627		<1%	545	$6K
82533		<1%	602	$6K
84154		<1%	611	$6K
87563		<1%	221	$6K
86593		<1%	2,083	$5K
86200		<1%	711	$5K
85379		<1%	902	$5K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	93	$5K
86617		<1%	391	$5K
86694		<1%	604	$5K
80377		<1%	3,328	$5K
86664		<1%	556	$4K
87506		<1%	21	$4K
84480		<1%	498	$4K
80305		<1%	565	$4K
82550		<1%	883	$4K
86141		<1%	398	$3K
86663		<1%	493	$3K
85045		<1%	1,263	$3K
82671		<1%	230	$3K
86769		<1%	70	$3K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	87	$3K
86317		<1%	343	$3K
85018		<1%	1,598	$2K
87493		<1%	129	$2K
80349		<1%	1,092	$2K
82951		<1%	231	$2K
85060		<1%	352	$2K
86850		<1%	364	$2K
80069		<1%	573	$2K
85014		<1%	1,225	$2K
87209		<1%	128	$2K
82947		<1%	635	$2K
87045		<1%	234	$2K
80346		<1%	1,174	$2K
86765		<1%	278	$2K
84134		<1%	165	$1K
83021		<1%	84	$1K
80361		<1%	1,119	$1K
86735		<1%	248	$1K
80364		<1%	1,069	$1K
84460		<1%	571	$1K
84450		<1%	530	$1K
84156		<1%	723	$1K
82040		<1%	709	$1K
85730		<1%	320	$1K
83992		<1%	948	$1K
G0103	Prostate cancer screening; prostate specific antigen test (psa)	<1%	480	$1K
86787		<1%	146	$1K
83883		<1%	148	$991.48
86708		<1%	198	$961.59
87505		<1%	14	$825.75
83520		<1%	52	$806.19
82784		<1%	75	$786.61
87177		<1%	127	$762.12
80375		<1%	1,202	$746.82
80353		<1%	1,047	$742.91
80359		<1%	1,044	$741.13
80372		<1%	1,123	$723.90
80373		<1%	1,128	$723.90
80348		<1%	1,182	$718.17
80365		<1%	1,130	$717.53
80354		<1%	1,150	$712.44
86901		<1%	464	$702.06
86900		<1%	463	$701.86
84466		<1%	103	$656.55
80358		<1%	1,125	$651.30
84132		<1%	307	$649.51
84207		<1%	27	$639.66
80156		<1%	61	$617.13
88142		<1%	41	$571.70
86618		<1%	65	$553.90
86008		<1%	45	$547.15
87517		<1%	64	$515.07
80321		<1%	660	$507.15
83695		<1%	59	$488.59
80185		<1%	63	$463.39
86160		<1%	38	$445.87
86308		<1%	179	$438.98
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	<1%	1,628	$421.57
83003		<1%	57	$413.62
83704		<1%	27	$410.58
87593		<1%	19	$392.52
80355		<1%	679	$369.83
80369		<1%	660	$364.10
80345		<1%	659	$352.64
86431		<1%	151	$348.85
80325		<1%	866	$347.06
80175		<1%	53	$335.38
80360		<1%	825	$329.87
80323		<1%	887	$325.26
80357		<1%	893	$318.41
82024		<1%	13	$299.12
82310		<1%	113	$292.90
82274		<1%	39	$289.68
84630		<1%	41	$258.63
84484		<1%	47	$243.12
84442		<1%	13	$232.08
86225		<1%	15	$222.56
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	13	$204.21
82985		<1%	15	$182.82
86702		<1%	22	$162.18
85660		<1%	35	$151.70
83921		<1%	16	$148.22
80324		<1%	186	$139.47
86039		<1%	27	$138.18
84520		<1%	123	$127.48
80165		<1%	36	$126.27
83615		<1%	30	$115.29
86701		<1%	22	$107.21
84432		<1%	12	$84.97
84478		<1%	45	$71.70
82565		<1%	17	$71.67
83527		<1%	13	$69.44
86707		<1%	13	$68.77
82962		<1%	35	$40.04
85049		<1%	19	$32.24
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	<1%	31	$2.07
80363		0%	41	$0.00
80343		0%	499	$0.00
80368		0%	515	$0.00
81225		0%	12	$0.00
81226		0%	12	$0.00
81227		0%	12	$0.00
80334		0%	509	$0.00
81291		0%	12	$0.00
80336		0%	515	$0.00
80339		0%	514	$0.00
80366		0%	513	$0.00
80332		0%	12	$0.00
80356		0%	40	$0.00
81479	Unlisted molecular pathology procedure	0%	48	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPRICE, CHAD (MANAGING MEMBER)